KRAS and cancer: However, SHP099 was found to be ineffective in KRAS-mutant or BRAF-mutant cancer cell lines [32], suggesting that the signalling and phenotypic effects of PTPN11 mutations and optimal targeting strategies may be impacted by co-existent mutations, particularly PIK3CA and RAS mutations.